Max Neeman Develops New Approach for Rare Disease Studies
Max Neeman International has established a team of experts specialized in carrying out rare disease trials in response to sponsor demand. The team has the required expertise to develop innovative approaches to optimize complex study design.
Max Neeman is a CRO in India that has a focus on Rare Disease Studies, in addition to other indications. Patient enrollment for rare disease, complex global and multi-centric trials is challenging because potential subjects are fewer in number and widely dispersed. India has evolved into a preferred destination for conducting such trials because of low cost and faster patient recruitment supported by the country's diverse gene pool and vast population of 1.3B.
Rare diseases are frequently life-threatening or chronically debilitating. However, drug development for these conditions has been limited by relative unavailability of subjects for clinical trials, as well as the high cost of investing in a novel pharmaceutical agent with poor market potential.
Max Neeman International conducts India-based clinical research services for clients across the globe.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
